Mayer, Sophie E <br/><br/>
CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy.  [electronic resource] 

 -  Cancer causes & control : CCC  Jan 2019 
 - 103-112 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1573-7225 
<br/><br/><label>Standard No.: </label>10.1007/s10552-018-1117-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Cohort Studies<br/>Cytochrome P-450 CYP2D6--genetics<br/>Cytochrome P-450 CYP2D6 Inhibitors--pharmacology<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local<br/>Phenotype<br/>Tamoxifen--therapeutic use